Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03113500 · ClinicalTrials.gov registry record · Phase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
A Phase 2 study of Angioimmunoblastic T-cell Lymphoma and Hepatosplenic T-cell Lymphoma, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 5
- Study locations
NCT03113500 is a Phase 2 study of Angioimmunoblastic T-cell Lymphoma and Hepatosplenic T-cell Lymphoma that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 48 participants, below the 68-participant average among 21 other Angioimmunoblastic T-cell Lymphoma trials with a reported enrollment target (29% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT03113500, a Phase 2 study of Angioimmunoblastic T-cell Lymphoma and Hepatosplenic T-cell Lymphoma, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase II trial studies the side effects and how well brentuximab vedotin and combination chemotherapy work in treating patients with CD30-positive peripheral T-cell lymphoma. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, etoposide, and prednisone work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin and combination chemotherapy may work better in treating patients with CD30-positive peripheral T-cell lymphoma.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Doxorubicin Hydrochloride
- DRUG Etoposide
- DRUG Brentuximab Vedotin
Study Locations (5)
California
- City of Hope Comprehensive Cancer Center - Duarte
New Jersey
- Hackensack University Medical Center - Hackensack
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Texas
- M D Anderson Cancer Center - Houston
British Columbia
- BCCA-Vancouver Cancer Centre - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2017-05-25 |
| Est. Completion | 2026-07-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03113500
The ClinicalTrials.gov registry entry for NCT03113500 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 68-participant average among 21 other Angioimmunoblastic T-cell Lymphoma trials with a reported enrollment target (29% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Angioimmunoblastic T-cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT03113500 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, New Jersey, Ohio.
Frequently Asked Questions
What is clinical trial NCT03113500 about?
NCT03113500 is a clinical study titled "Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma". This phase II trial studies the side effects and how well brentuximab vedotin and combination chemotherapy work in treating patients with CD30-positive peripheral T-cell lymphoma. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches ...
What is the current status of trial NCT03113500?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2017-05-25. Estimated completion is 2026-07-07.
What conditions does trial NCT03113500 study?
This clinical trial studies the following conditions: Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Adult T-cell Leukemia/Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT03113500?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Doxorubicin Hydrochloride (DRUG), Etoposide (DRUG), Brentuximab Vedotin (DRUG).
Who is sponsoring clinical trial NCT03113500?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03113500 being conducted?
This trial has 5 study locations across California, New Jersey, Ohio, Texas, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Angioimmunoblastic T-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
COMPLETED · Phase 2
-
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
COMPLETED · Phase 2
-
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
COMPLETED · Phase 2
-
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
COMPLETED · Phase 2
-
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
RECRUITING · Phase 3
Explore more on PlainTrial
Angioimmunoblastic T-cell Lymphoma
All registered trials for this condition
Hepatosplenic T-cell Lymphoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.